<![CDATA[Vitruvias Therapeutics Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=32114>Thu, 30 Apr 2026 18:02:56 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Vitruvias Therapeutics Inc., Licenses Potassium Chloride ER ANDA (10 and 20 mEq) Capsules to Be Manufactured at Bora Pharmaceutical’s New Zhunan Facility in Taiwan]]>https://www.newswire.co.kr/newsRead.php?no=880359Mon, 10 Dec 2018 10:05:00 +0900<![CDATA[비트루비아스 테라퓨틱스(Vitruvias Therapeutics Inc.), 대만 소재 보라 제약(Bora Pharmaceutical) 주난(Zhunan) 제조시설과 염화칼륨 서방정(10, 20 밀리그램당량) 위탁생산 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=880360Mon, 10 Dec 2018 10:05:00 +0900<![CDATA[Vitruvias Therapeutics Inc., and Sunny Pharmtech Inc., Announce the FDA Approval of Generic Aminocaproic Acid 500 mg and 1000 mg Tablets]]>https://www.newswire.co.kr/newsRead.php?no=879998Mon, 03 Dec 2018 20:00:00 +0900<![CDATA[비트루비아스 테라퓨틱스와 서니 팜테크, 제네릭 아미노카프론산 500 mg 및 1000 mg 정제에 대한 FDA 승인 발표]]>https://www.newswire.co.kr/newsRead.php?no=879999Mon, 03 Dec 2018 20:00:00 +0900